SGLT2 inhibitors and euglycemic diabetic ketoacidosis
- PMID: 33687516
- DOI: 10.1007/s00228-021-03120-1
SGLT2 inhibitors and euglycemic diabetic ketoacidosis
Comment on
-
Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.Eur J Clin Pharmacol. 2021 May;77(5):651-657. doi: 10.1007/s00228-020-03051-3. Epub 2020 Nov 26. Eur J Clin Pharmacol. 2021. PMID: 33244632 Review.
References
-
- Bamgboye AO, Oni IO, Collier A (2020) Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-020-03051-3
-
- Clark A, Mohammed AS, Raut A, Moore S, Houlden R, Awad S (2020) Prevalence and clinical characteristics of adults presenting with sodium-glucose cotransporter-2 inhibitor-associated diabetic ketoacidosis at a Canadian Academic Tertiary Care Hospital. Can J Diabetes. https://doi.org/10.1016/j.jcjd.2020.08.100
-
- Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535 - DOI - PubMed - PMC
-
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012. https://doi.org/10.1001/jama.283.15.2008 - DOI - PubMed
-
- Lo CK, Mertz D, Loeb M (2014) Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 14:45. https://doi.org/10.1186/1471-2288-14-45 - DOI - PubMed - PMC